Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Sep;1(5):422-7.
doi: 10.1007/s11910-001-0101-z.

Amyloid Metabolism and Secretases in Alzheimer's Disease

Affiliations
Review

Amyloid Metabolism and Secretases in Alzheimer's Disease

W Xia. Curr Neurol Neurosci Rep. .

Abstract

Alzheimer's disease (AD) is characterized by the progressive accumulation of amyloid fibrils composed of the amyloid beta-protein (A beta) in senile plaques. A beta is derived from the beta-amyloid precursor protein (APP) after beta- and gamma-secretase cleavages. beta-secretase was recently identified to be a membrane-anchored aspartyl protease that is widely distributed in subcellular compartments, including Golgi, trans-Golgi network, and endosomes. Although definitive identification of gamma-secretase will require reconstituting its activity in vitro, mounting evidence suggests that gamma-secretase is an unusual intramembrane-cleaving aspartyl protease. Two intramembranous aspartate residues in presenilin (PS) are absolutely required for A beta generation. Three classes of gamma-secretase inhibitors can directly bind to PS, strongly supporting the hypothesis of PSI as gamma-secretase. These results provide the molecular basis for therapeutic interventions that reduce A beta accumulation in AD patients by inhibiting beta- or gamma-secretase.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. J Biol Chem. 2000 Jul 14;275(28):21099-106 - PubMed
    1. Nature. 1999 Dec 2;402(6761):533-7 - PubMed
    1. Neurobiol Dis. 2000 Dec;7(6 Pt B):673-81 - PubMed
    1. J Biol Chem. 1999 Sep 3;274(36):25945-52 - PubMed
    1. Nature. 2000 Sep 7;407(6800):48-54 - PubMed

MeSH terms

LinkOut - more resources

Feedback